US3019171A - Activated enzyme compositions - Google Patents
Activated enzyme compositions Download PDFInfo
- Publication number
- US3019171A US3019171A US698366A US69836657A US3019171A US 3019171 A US3019171 A US 3019171A US 698366 A US698366 A US 698366A US 69836657 A US69836657 A US 69836657A US 3019171 A US3019171 A US 3019171A
- Authority
- US
- United States
- Prior art keywords
- enzyme
- pinguinain
- magnesium
- calcium
- eschar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 38
- 108090000790 Enzymes Proteins 0.000 title claims description 38
- 239000000203 mixture Substances 0.000 title claims description 23
- 229940088598 enzyme Drugs 0.000 claims description 37
- 239000004365 Protease Substances 0.000 claims description 22
- 108010034248 pinguinain Proteins 0.000 claims description 19
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 18
- 229910052749 magnesium Inorganic materials 0.000 claims description 18
- 229910021645 metal ion Inorganic materials 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 102000035195 Peptidases Human genes 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 108010004032 Bromelains Proteins 0.000 claims description 14
- 239000010941 cobalt Substances 0.000 claims description 13
- 229910017052 cobalt Inorganic materials 0.000 claims description 13
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 13
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 12
- 229910052748 manganese Inorganic materials 0.000 claims description 12
- 239000011572 manganese Substances 0.000 claims description 12
- 231100000252 nontoxic Toxicity 0.000 claims description 12
- 230000003000 nontoxic effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 231100000028 nontoxic concentration Toxicity 0.000 claims description 11
- 108090000270 Ficain Proteins 0.000 claims description 8
- 235000019836 ficin Nutrition 0.000 claims description 8
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 claims description 8
- 108090000526 Papain Proteins 0.000 claims description 7
- 235000019835 bromelain Nutrition 0.000 claims description 7
- 229940055729 papain Drugs 0.000 claims description 7
- 235000019834 papain Nutrition 0.000 claims description 7
- 108090000101 Asclepain Proteins 0.000 claims description 6
- UNMLVGNWZDHBRA-UHFFFAOYSA-N N-[2-[5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl]oxy-5-[4,5-dihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(CO)O4)O)O3)OC3C(C(O)C(O)CO3)O)C(CO)O2)NC(C)=O)C(CO)OC(O)C1NC(C)=O UNMLVGNWZDHBRA-UHFFFAOYSA-N 0.000 claims 1
- 206010051814 Eschar Diseases 0.000 description 17
- 231100000333 eschar Toxicity 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 13
- 235000018417 cysteine Nutrition 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 108010027805 Azocoll Proteins 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 244000182625 Dictamnus albus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- -1 potassium and sodium Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 240000004555 Bromelia pinguin Species 0.000 description 1
- 235000001839 Bromelia pinguin Nutrition 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
Definitions
- enzymes are not as ble, their characteristics are usually established along functional lines. Thus, it is typical of some enzymes that they are, under optimal conditions of temperature, either inhibited or not aifected at all when chemical agents are Others demonstrate an accelerated acyet structurally identifiazymes are completely inactive in the absence of chemi- Agents which are capable of increasing the activity of such weakly active or inactive enzymes are called activators.
- proteolytic enzymes are activated inthe presence of ions of calcium, magnesium, manganese, cobalt or combinations thereof.
- Preferred for use as single activators are calcium and magnesium. Where a combination of two metals is employed to activate the enzyme, calcium and magnesium I are preferred.
- the proportions of the metal ions to be used in activating proteolytic enzymes according to this invention may be varied considerably, depending upon the number of different activating ions employed, the pH of the final product desired and other factors. Satisfactory results are obtained when the ions are added in a non-toxic concentration from about 0.01 molar to about 1.0 molar. For optimal activation, it is preferred to use a concentration from about 0.05 molar to about 0.1 molar.
- Useful non-toxic salts of the metal ion activators include chlorides, acetates, lactates, propionates, gluconates and, preferably, phosphates.
- alkali some enmetal ions, i.e. potassium and sodium, preferably in the form of phosphates or acetates, is advantageous primarily for the purpose of buffering the enzyme compositions.
- a reducing agent such as a thiosulfate, i.e. sodium or potassium or, preferably, cysteine in order to obtain maximum results.
- cysteine in a concentration from about 0.05 molar to about 0.1 molar is satisfactory.
- proteolytic enzyme as used herein is meant to include pinguinain, papain, ficin, bromelin, bromelain and asclepain.
- Preferred for use as the proteolytic enzyme is pinguinain or ficin; especially preferred is pinguinain.
- Pinguinain as used in this invention is meant to include the proteolytic enzyme described by Asenjo (Science, v. 95, No. 2454, pp. 48-49) as well as the improved form of pinguinain obtained by macerating the fruit of Bromelia pinguin, separating the juice from the fibrous debris, spray-drying and, if desired, further purifying by precipitation with ammonium sulfate, aqueous methanol, aqueous ethanol or aqueous isopropanol.
- Pinguinain is a high molecular weight enzyme system comprised essentially of three components, two of which (A and B) are proteinaceous in character and readily characterizable by their mobilities in an electrophoretic field, the third (C) being non-protein and lacking in electrophoretic mobility between pH 3.5 and pH 6.0.
- the average electrophoretic mobility in 0.1 ionic glycine buffer at pH 3.5 for A component is 0.377, for B componeut it is 0.234.
- the average mobility in acetate buffer at pH 4.6 for A component is 0.175, for B component it is 0.064.
- the isoelectric point for A component is above pH 6.0, for B component pH 5.25.
- the enzyme demonstrates optimal proteolytic activity (in an Azocoll substrate) at a pH from about 5.2 to about 5.5 and at pH 7.3, and is inactivated at temperatures in excess of C. It is not activated by ascorbic acid, but is activated by sodium thiosulfate and cysteine. It is soluble in water, normal saline and aqueous salt solutions of low ionic strength.
- the activated enzymes of this invention may be used in the form of aqueous solutions either for topical administration or for intramuscular injection. They may also be used in the form of gels suitable for application on burned or ulcerated areas.
- the quantity about 0.01% to about 1%, preferably about 0.5% en zyme on a weight basis, or from about 1,000 to about 20,000 Azocoll units per milliliter. Similar proportions may be employed when any one of the other enzymes specified hereinabove is formulated.
- activated enzyme solutions and gels for topical use should be adjusted to a pH from about 3.0 to about 5.0 with an appropriate buffer, preferably acetate or phosphate. Solutions intended for intramuscular injection should be adjusted to near neutrality. The utility of this material for use in human therapy has not as yet been clinically established.
- vegetable gums such as acacia, tragacanth, ghatti or karaya
- mucilages such as those obtained from guar, bean, linseed, the locust bean or other related leguminous plant seeds
- cellulose derivatives such as carboxymethylcellulose, methylcellulose, starch or starch derivatives.
- altliough'the activated enzyme compositions of this invention may find primary application as debriding and anti-inflammatory agents, they are also useful in a wide variety of industrial processes where proteolytic enzymes are conventionally employed, as for example in chill-proofing of beer, cheese-making, leather manufacture, as meat .tcnderizers, etc., and it is intended that these applications be included within the scope of this invention.
- the Azocoll unit as used herein is an index of proteolytic activity as determined by the method of Bidwell (Biochemical Journal, 46, pp. 589-598, 1950) and Oakley et al. (Journal of Pathology and Bacteriology, 58, pp. 229235, 1946).
- Enhancement of proteolytic activity in the presence of metal ions is demonstrable by means of tests on guinea pig eschar.
- the procedure is as follows: The hair is removed from a guinea pig back with an animal hair clip- *vati'ons of the percentageof eschar Value Description No activity.
- the activating eifect of metal ions on proteolytic enzymes is also evidenced by in vivo tests on guinea pig eschar.
- the procedure is as follows: Hair is removed from a guinea pig back with an animal hair clipper. The animal is then injected with sodium pentobarbital. The animals back is then immersed in a water bath-'at'70" C. for 45 seconds. A burned areaof about two to three inches in diameter-is formed as a result of this immersion. Seven days after the burn, the animal is treated with the enzyme preparation, applied 'in ointinent form to the burned area on three successive days. The ointment is covered with a film'which is kept-inplace-b'y tape.
- the eschar is then inspected Phata bllfier' l 3g 3g visually and the activity of the preparation is evaluated.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain and, in non-toxic concentration, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at nontoxic concentrations, and a buffer.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and as clepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a butter and cysteine.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a butter and an alkali metal thiosulfate.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at nontoxic concentrations, a butler, cysteine and a pharmaceutical carrier.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain and, in non-toxic concentration at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their nontoxic salts.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinuinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations and a buffer.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concen trations, a buffer and cysteine.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the :form of their non-toxic salts, a buffer and an alkaline metal thiosulfate.
- An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a bufier, cysteine and a pharmaceutical carrier.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
added to them. tivity in the presence of chemicals.
cal additives.
United States Patent tion of New Jersey No Drawing. Filed Nov. 25, 1957, Ser. No. 698,366
16 Claims. (Cl. 195-68) This invention relates to the activation of proteolytic enzymes.
In recent years a considerable amount of research effort has been devoted to the study of a class of biological catalysts commonly known as enzymes. Notable advances have been made in this field and vast quantities of scientific data have been accumulated regarding physiological and chemical properties of enzymes. A number of them have been prepared in highly purified form and their chemical constitution has been studied in detail. It has been established, for example, that enzymes are largely protein in nature; that their essential structural unit is a long chain arising from the condensation of a number of amino acid residues joined through peptide linkage; that they are large size molecules of high molecular weight; and that, in solution, they migrate characteristically in an electrical field.
Because enzymes are not as ble, their characteristics are usually established along functional lines. Thus, it is typical of some enzymes that they are, under optimal conditions of temperature, either inhibited or not aifected at all when chemical agents are Others demonstrate an accelerated acyet structurally identifiazymes are completely inactive in the absence of chemi- Agents which are capable of increasing the activity of such weakly active or inactive enzymes are called activators.
The search for suitable activators has been considerj ably intensified'in recent years due to the discovery that f proteolytic enzymes are useful in the medical field in the physiological debridement of eschar, blood and pus. Al-
though a large number of proteolytic enzymes are available, laboratory tests show that their proteolytic activity is weak and slow in onset, thus reducing their applicability from an industrial point of view.
It has now been found that certain proteolytic enzymes are activated inthe presence of ions of calcium, magnesium, manganese, cobalt or combinations thereof.
Preferred for use as single activators are calcium and magnesium. Where a combination of two metals is employed to activate the enzyme, calcium and magnesium I are preferred. The proportions of the metal ions to be used in activating proteolytic enzymes according to this invention may be varied considerably, depending upon the number of different activating ions employed, the pH of the final product desired and other factors. Satisfactory results are obtained when the ions are added in a non-toxic concentration from about 0.01 molar to about 1.0 molar. For optimal activation, it is preferred to use a concentration from about 0.05 molar to about 0.1 molar.
Useful non-toxic salts of the metal ion activators include chlorides, acetates, lactates, propionates, gluconates and, preferably, phosphates. The addition of alkali In fact, some enmetal ions, i.e. potassium and sodium, preferably in the form of phosphates or acetates, is advantageous primarily for the purpose of buffering the enzyme compositions. For topical use on the animal organism it has been found that adjustment of pH from about 3.0 to about 5.0, optimally from about 3.0 to about 4.0 is satisfactory. Further, it is also desirable to include a reducing agent such as a thiosulfate, i.e. sodium or potassium or, preferably, cysteine in order to obtain maximum results. The inclusion of cysteine in a concentration from about 0.05 molar to about 0.1 molar is satisfactory.
The term proteolytic enzyme as used herein is meant to include pinguinain, papain, ficin, bromelin, bromelain and asclepain. Preferred for use as the proteolytic enzyme is pinguinain or ficin; especially preferred is pinguinain.
Pinguinain as used in this invention is meant to include the proteolytic enzyme described by Asenjo (Science, v. 95, No. 2454, pp. 48-49) as well as the improved form of pinguinain obtained by macerating the fruit of Bromelia pinguin, separating the juice from the fibrous debris, spray-drying and, if desired, further purifying by precipitation with ammonium sulfate, aqueous methanol, aqueous ethanol or aqueous isopropanol. Pinguinain is a high molecular weight enzyme system comprised essentially of three components, two of which (A and B) are proteinaceous in character and readily characterizable by their mobilities in an electrophoretic field, the third (C) being non-protein and lacking in electrophoretic mobility between pH 3.5 and pH 6.0. The average electrophoretic mobility in 0.1 ionic glycine buffer at pH 3.5 for A component is 0.377, for B componeut it is 0.234. The average mobility in acetate buffer at pH 4.6 for A component is 0.175, for B component it is 0.064. The isoelectric point for A component is above pH 6.0, for B component pH 5.25. .The enzyme demonstrates optimal proteolytic activity (in an Azocoll substrate) at a pH from about 5.2 to about 5.5 and at pH 7.3, and is inactivated at temperatures in excess of C. It is not activated by ascorbic acid, but is activated by sodium thiosulfate and cysteine. It is soluble in water, normal saline and aqueous salt solutions of low ionic strength.
In actual practice, the activated enzymes of this invention may be used in the form of aqueous solutions either for topical administration or for intramuscular injection. They may also be used in the form of gels suitable for application on burned or ulcerated areas. The quantity about 0.01% to about 1%, preferably about 0.5% en zyme on a weight basis, or from about 1,000 to about 20,000 Azocoll units per milliliter. Similar proportions may be employed when any one of the other enzymes specified hereinabove is formulated. To ensure maximum proteolytic activity, activated enzyme solutions and gels for topical use should be adjusted to a pH from about 3.0 to about 5.0 with an appropriate buffer, preferably acetate or phosphate. Solutions intended for intramuscular injection should be adjusted to near neutrality. The utility of this material for use in human therapy has not as yet been clinically established.
Among the substances suitable for formulation of activated enzyme gels there may be mentioned vegetable gums such as acacia, tragacanth, ghatti or karaya; mucilages such as those obtained from guar, bean, linseed, the locust bean or other related leguminous plant seeds; or cellulose derivatives such as carboxymethylcellulose, methylcellulose, starch or starch derivatives. It is to be understood that altliough'the activated enzyme compositions of this invention may find primary application as debriding and anti-inflammatory agents, they are also useful in a wide variety of industrial processes where proteolytic enzymes are conventionally employed, as for example in chill-proofing of beer, cheese-making, leather manufacture, as meat .tcnderizers, etc., and it is intended that these applications be included within the scope of this invention.
The Azocoll unit as used herein is an index of proteolytic activity as determined by the method of Bidwell (Biochemical Journal, 46, pp. 589-598, 1950) and Oakley et al. (Journal of Pathology and Bacteriology, 58, pp. 229235, 1946).
Enhancement of proteolytic activity in the presence of metal ions is demonstrable by means of tests on guinea pig eschar. The procedure is as follows: The hair is removed from a guinea pig back with an animal hair clip- *vati'ons of the percentageof eschar Value Description No activity.
Separation of layers with little or no digestion.
. Separation of layers and some digestion.
Fair diglcstion with few small pieces broken ofi the main body of esc ar.
Good digestion with the eschar partially disintegrated.
Escher completely disintegrated with a few small particles remaining.
Eschar completely disintegrated.
The activating eifect of metal ions on proteolytic enzymes is also evidenced by in vivo tests on guinea pig eschar. The procedure is as follows: Hair is removed from a guinea pig back with an animal hair clipper. The animal is then injected with sodium pentobarbital. The animals back is then immersed in a water bath-'at'70" C. for 45 seconds. A burned areaof about two to three inches in diameter-is formed as a result of this immersion. Seven days after the burn, the animal is treated with the enzyme preparation, applied 'in ointinent form to the burned area on three successive days. The ointment is covered with a film'which is kept-inplace-b'y tape. Obserwhich was debrided on each animal tested are recorded each day "that'the bandages are removed. The bandage is'r'emoved an'd'the eschar is observed on thefirstfsecond and third days "after the initial application of enzyme. The ointment employe'din these testseonsiste'rl of 3 gfiof guarguin, 1.8 g. of pinguinain and 30ml. of'water. The enzyme 'andgum were mixed in a'drystate and'added to'the water immediately before use.
Results of in vivo tests onguinea pig'escharemploying pinguinain are given below. The fi'gure"percent debridement represents the percentage of the'eschar which was debrided on the'animal tested. Complete cleaning of'the per. The animal is then injected with sodium pentodt h b1 f d 1007 barbital. The animals back is then immersed in a water Woun 0 e vla e gra t tlssue 1S cons ere .3.
O bath at 70 -C. f0r 45 seconds. A burned area of about Amount. Percent debridement 2 to 3 inches in diameter is formed as a result of this ofenz yi ie immersion. Seven days after the animal has been g i 1 3 n h animal Dilucnt I blll'l'lci'lt is sacrificed and th eschar is hari ested. T e in tom 7 24 hrs 48 hrs. 72 hrs eschar is removed from the animal with a scalpel and treatment stored in the frozen state until needed for use. Immedi- $322 ateiy before use, while it is still in the frozen state, the I escha-r is cut into pieces 1 X 1 cm. for a 5 ml. volumc'of 220x10 Acetate 50 reaction mixture; 1 x 2 cm. for a 10 ml. volume of re- 3% action mixture, and l x 3 cm. for a 15 ml. volume of ,3 reaction mixture. The eschar pieces are permitted to 420x10 Watei' 5 5 e5 thaw about vl0 minutes before they are placedun the 381x103; MM calcium cmmdemetate ,5 ,90 100 reaction mixtures. The reaction mixture containing a butter. g: 100 piece of eschar is incubated in an oven at 37 C. for be- 381mm calcium chloride 32 tween 16 and 18 hours. The eschar is then inspected Phata bllfier' l 3g 3g visually and the activity of the preparation is evaluated. 55 381x10 oli a magn sium chloride lies '5 97 100 'lgte term reaction mixture asl used in these 'gests means 381x10, Z E L' cboridley 5 g3 32 533 t mixtur o. "si 0 sciar u st ate t enz e magnesium w P 9 100 the e S b r e ym 1 phosphate butler. i 25 99 100 ant. the particular carrier employed. 38l l0 0.05M calcium eligiridg, 0.95M 85 98 100 1 magnesium act p osp iate 75 '95 '100 Follow ng are the results of in vitro tests on guinea pig 60 phosphate bufien 50 95 l eschar using pinguinain:
Enzyme Azocoll Cone. of
c0110., value Buffer pH cysteine Metaliou Result: percent units/ml. (M)
6 285x10 3.4 0.008111 No 2 e 285x10 3.4 0. 008m 0.2M eobaiteliiondaunn 4 6 285 10 3.4 0. 008m 02M manganese ChlOIldtL- 3 0 285x10 2 3. 4 0. 008m 0.02M magnesium chloilde 5 6 285x10 3.4 0. 008m 0.2M cobalt'chlor'ide e 6 285 10 3.4 0.008m 0.2M manganese chloride 7 6 285x10 3.4 0. 008m 0.2M magnesium chloride '6 4 182 10 4.3 0.05 m 0.2M calcium chloride 7 10 27OX10 2 3.0 0. 008m 0.02M calcium chloride, 0.04M m. 6 10 270x10 Water 4.0 0.008m .do- 7 1o 270x10 Water-NaOH... 5.2 0. 008m do 5 10 270x10 o as 0. 008m 0.--- 2 The following tests illustrate the activating ability of metal ions on other proteolytic enzymes. The tests were conducted as follows: A 1 x 1 cm. piece of eschar was placed in each enzyme solution ml). The enzyme solution was prepared by weighing enzyme quantities and cysteine and adding 20 ml. of diluent activator, or buffer without activator as the case may be, to the weighed quantities of enzyme. One piece of eschar was added to 5 ml. of enzyme solution in a test tube. The reaction mixture was incubated in an oven at 37 C. for between 16 and 18 hours and the results of the test evaluated. The diluent activator used in these tests (and which may be employed in actual practice for the purposes specified hereinabove) had the following composition:
G. Calcium chloride 0.55 Magnesium acid phosphate 1.09 Disodium phosphate 0.057 Distilled water, q.s. 100.00 ml.
The results are as follows:
Enzyme Diluent Cysteine, pH Results 2g. papain- 0.1M sodium ace- 120 4. 3 Esehar partially tate pH 3.75. disintegrated. Do Dlluent activator- 120 4. 3 Eschar completely disintegrated. 2g. flcin-- 0.1M sodium ace- 120 4. 4 Escher partially tate pH 3.75. disintegrated. Do Diluent activator- 120 4. 4 Escher completely disintegrated.
What is claimed is:
1. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain and, in non-toxic concentration, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts.
2. A composition as set forth in claim 1 wherein the metal ions are contained in a concentration from about 0.01 molar to about 1.0 molar.
3. A composition as set forth in claim 1 wherein the metal ions are contained in a concentration from about 0.05 molar to about 0.1 molar.
4. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at nontoxic concentrations, and a buffer.
5. A composition as set forth in claim 4 wherein the buffer is an acetate.
6. A composition as set forth in claim 4 wherein the buifer is a phosphate.
7. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and as clepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a butter and cysteine.
8. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a butter and an alkali metal thiosulfate.
9. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising a plant proteolytic enzyme selected from the group consisting of pinguinain, papain, ficin, bromelin, bromelain and asclepain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at nontoxic concentrations, a butler, cysteine and a pharmaceutical carrier.
10. A composition as set forth in claim 9 wherein the pharmaceutical carrier is an aqueous carrier.
11. A composition as set forth in claim 9 wherein the pharmaceutical carrier is a gel.
12. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain and, in non-toxic concentration at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their nontoxic salts.
13. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinuinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations and a buffer.
14. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concen trations, a buffer and cysteine.
15. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the :form of their non-toxic salts, a buffer and an alkaline metal thiosulfate.
16. An activated enzyme composition adjusted to a pH of from about 3.0 to about 5.0 comprising pinguinain, at least one metal ion selected from the group consisting of calcium, magnesium, manganese and cobalt in the form of their non-toxic salts and at non-toxic concentrations, a bufier, cysteine and a pharmaceutical carrier.
References Cited in the file of this patent UNITED STATES PATENTS Holmbacker Oct. 24, 1950 Damaskus Apr. 4, 1961 OTHER REFERENCES Sumner et al.: Chemistry and Methods of Enzymes, 3rd Ed., 1953, Academic Press, N.Y., pp. 166-198, pp. 187 and 189-191 esp. pertinent.
Grob: J. Gen. Physiology, 29:4, March 20, 1946, pp. 223, 227, 233 and 235-237.
Kimmel et al.: J. Biol. Chem., Vol. 207, pp. 515-531, 1954.
Hwang et al.: Ann. N.Y. Acad. 191-196, 204-207, May 16, 1951.
Gold et al.: Amer. J. of the Med. Sciences, Vol. 228, pp. 568-585, 1954.
Science News Letter, 70:20, Nov. 17, 1956, p. 312.
Heilesen: J. Inv. Dermatology, 23:1, pp. 7-15, July 1954.
Altemeier et al.: Annals October 1951.
Sherry et al.: Procs. of the Sec. for Exptl. Biol. and Med, 87:1, pp. -128, October 1954.
Chemical Abstracts (1), vol. 48, p. 5243g, 1954.
Chemical Abstracts (2), vol. 45, p. 7165i, 1951.
Sciences, 54:2, pp.
Surg. 134:4, pp. 581-583,
Claims (1)
1. AN ACTIVATED ENZYME COMPOSITION ADJUSTED TO A PH OF FROM ABOUT 3.0 TO ABOUT 5.0 COMPRISING A PLANT PROTEOLYTIC ENZYME SELECTED FROM THE GROUP CONSISTING OF PINGUINAIN, PAPAIN, FICIN, BROMELIN, BROMELAIN AND ASCLEPAIN AND, IN NON-TOXIC CONCENTRATION, AT LEAST ONE METAL ION SELECTED FROM THE GROUP CONSISTING OF CALCIUM, MAGNESIUM, MANGANESE AND COBALT IN THE FORM OF THEIR NON-TOXIC SALTS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US698366A US3019171A (en) | 1957-11-25 | 1957-11-25 | Activated enzyme compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US698366A US3019171A (en) | 1957-11-25 | 1957-11-25 | Activated enzyme compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US3019171A true US3019171A (en) | 1962-01-30 |
Family
ID=24804932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US698366A Expired - Lifetime US3019171A (en) | 1957-11-25 | 1957-11-25 | Activated enzyme compositions |
Country Status (1)
Country | Link |
---|---|
US (1) | US3019171A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3223593A (en) * | 1963-08-14 | 1965-12-14 | Melpar Inc | Method of preparing immobilized serum cholinesterase and product thereof |
US3296094A (en) * | 1966-05-05 | 1967-01-03 | Baxter Laboratories Inc | Stabilized aqueous enzyme solutions |
US3384552A (en) * | 1965-06-21 | 1968-05-21 | Army Usa | Dry solid proteolytic enzyme isolated from pinguinain |
US3506582A (en) * | 1966-11-10 | 1970-04-14 | Miles Lab | Drain cleaner composition and process |
US3627683A (en) * | 1968-11-19 | 1971-12-14 | Procter & Gamble | Detergent composition |
US3956483A (en) * | 1968-10-24 | 1976-05-11 | Wilson Pharmaceutical & Chemical Corporation | Preparing pancreatin |
US4048416A (en) * | 1974-05-30 | 1977-09-13 | Exploaterings Aktiebolaget T.B.F. | Thiopolymers, their derivatives and methods for their preparation and use |
US4055635A (en) * | 1973-07-05 | 1977-10-25 | Beecham Group Limited | Fibrinolytic compositions |
US4115546A (en) * | 1975-03-12 | 1978-09-19 | Colgate Palmolive Company | Oral compositions containing dextranase |
US4228240A (en) * | 1976-09-24 | 1980-10-14 | Akzona Incorporated | Stabilization of peroxidase |
US4342743A (en) * | 1981-02-24 | 1982-08-03 | Panton Moore Lithia | Preparation for the care and conditioning of the feet |
US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US6548556B2 (en) | 2000-12-27 | 2003-04-15 | Healthpoint, Ltd. | Stable enzymatic wound debrider |
US20080248159A1 (en) * | 2004-03-31 | 2008-10-09 | Pascal Julien | Bread-Making Improver |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2527305A (en) * | 1948-12-10 | 1950-10-24 | Paul Lewis Lab Inc | Fat rendering process |
US2978385A (en) * | 1957-07-05 | 1961-04-04 | Armour & Co | Stabilized chymotrypsin solution |
-
1957
- 1957-11-25 US US698366A patent/US3019171A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2527305A (en) * | 1948-12-10 | 1950-10-24 | Paul Lewis Lab Inc | Fat rendering process |
US2978385A (en) * | 1957-07-05 | 1961-04-04 | Armour & Co | Stabilized chymotrypsin solution |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3223593A (en) * | 1963-08-14 | 1965-12-14 | Melpar Inc | Method of preparing immobilized serum cholinesterase and product thereof |
US3384552A (en) * | 1965-06-21 | 1968-05-21 | Army Usa | Dry solid proteolytic enzyme isolated from pinguinain |
US3296094A (en) * | 1966-05-05 | 1967-01-03 | Baxter Laboratories Inc | Stabilized aqueous enzyme solutions |
US3506582A (en) * | 1966-11-10 | 1970-04-14 | Miles Lab | Drain cleaner composition and process |
US3956483A (en) * | 1968-10-24 | 1976-05-11 | Wilson Pharmaceutical & Chemical Corporation | Preparing pancreatin |
US3627683A (en) * | 1968-11-19 | 1971-12-14 | Procter & Gamble | Detergent composition |
US4055635A (en) * | 1973-07-05 | 1977-10-25 | Beecham Group Limited | Fibrinolytic compositions |
US4048416A (en) * | 1974-05-30 | 1977-09-13 | Exploaterings Aktiebolaget T.B.F. | Thiopolymers, their derivatives and methods for their preparation and use |
US4115546A (en) * | 1975-03-12 | 1978-09-19 | Colgate Palmolive Company | Oral compositions containing dextranase |
US4140758A (en) * | 1975-03-12 | 1979-02-20 | Colgate-Palmolive Company | Oral compositions containing dextranase |
US4228240A (en) * | 1976-09-24 | 1980-10-14 | Akzona Incorporated | Stabilization of peroxidase |
US4331761A (en) * | 1976-09-24 | 1982-05-25 | Akzona Incorporated | Stabilization of peroxidase |
US4342743A (en) * | 1981-02-24 | 1982-08-03 | Panton Moore Lithia | Preparation for the care and conditioning of the feet |
US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US6548556B2 (en) | 2000-12-27 | 2003-04-15 | Healthpoint, Ltd. | Stable enzymatic wound debrider |
US20080248159A1 (en) * | 2004-03-31 | 2008-10-09 | Pascal Julien | Bread-Making Improver |
US8802182B2 (en) * | 2004-03-31 | 2014-08-12 | Lesaffre Et Compagnie | Bread-making improver |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3019171A (en) | Activated enzyme compositions | |
Sgouris et al. | The preparation of human fibrinolysin (plasmin) | |
Polakoski et al. | Boar proacrosin. Purification and preliminary activation studies of proacrosin isolated from ejaculated boar sperm. | |
Morrison et al. | Cathepsins B1 and D. Action on human cartilage proteoglycans | |
Hobson | Determination of polygalacturonase in fruits | |
EP0123304B1 (en) | A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same | |
Porges | Snake venoms, their biochemistry and mode of action | |
IE852323L (en) | Blood coagulation inhibiting proteins | |
Vermeer et al. | Vitamin K-dependnet carboxylases from non-hepatic tissues | |
US4329430A (en) | Enzyme mixture | |
Noguchi et al. | Purification and properties of a new alkaline protease of rat skeletal muscle | |
US4374830A (en) | Platelet aggregating material from equine arterial tissue | |
Fantl | A comparative study of blood coagulation in vertebrates | |
US5387517A (en) | Thiol activated protease from stem bromelain for treating devitalized tissue | |
US4177262A (en) | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots | |
Stoughton | Enzymatic cytolysis of epithelium by filtrates of feces from patients with ulcerative colitis | |
US5354269A (en) | Method for treating cancer resections | |
US2977287A (en) | Enzyme and method for preparation | |
US4012502A (en) | Snake venom inhibitor material and method of purification | |
US5945103A (en) | Process for producing thrombin | |
McCall et al. | Mechanism of action and some properties of a tissue activator of plasminogen | |
GB1581472A (en) | Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them | |
EP0151996B1 (en) | Process for the preparation of a double-chain plasminogen activator | |
Tolnai | Purification and some characteristics of a Ca2+-activated proteolytic enzyme from beef cardiac muscle | |
US2624691A (en) | Fibrinolysin derived from blood and methods of obtaining the same |